Cardiothoracic surgeons at the University of Louisville Health – Jewish Hospital and the University of Louisville performed the first-ever Aeson bioprosthetic total artificial heart implantation on a 57-year-old woman from Kentucky.
EurêkAlert! reported that she is the first woman to receive the new type of artificial heart, but overall the third person to do so after two men who received the artificial heart in recent months. The cardiothoracic surgery team performed the heart transplant on September 14, 2021 at UofL Health – Jewish Hospital.
(Photo: Getty Images)
A CARMAT employee shows a self-regulating bioprosthetic artificial heart at the company’s headquarters in Bois-d’Arcy, west of Paris, August 29, 2018 (Photo BERTRAND GUAY / AFP)
First woman to receive an Aeson artificial total heart transplant
According to Yale Medicine, more than 3,500 people in the United States are waiting for a heart transplant. Most of them will wait more than six months to get a new heart, but some will die before it becomes available to them. This is why breakthroughs in heart transplantation are important.
Like EurekAlert! reported, the Aeson device under the Early Feasibility Study (EFS) sponsored by the French medical device company CARMAT is designed as a gateway to heart transplants. It overcomes the limitations of left ventricular assist devices (LVADs) by pumping blood into both chambers of the heart.
In addition, it contains pressure sensors that estimate blood pressure and automatically adapt cardiac output. It is totally transplanted as a heart replacement and powered by a portable power supply.
Cardiothoracic surgeons Mark Slaughter, MD, and Siddharth Pahwa, MD, who led the transplant, said the Aeson artificial heart is compact enough to fit into smaller chest cavities, especially in women, which provides l hope for a greater variety of patients waiting for a heart transplant and increases the success rate.
The Aeson artificial heart was transplanted into a 57-year-old woman who suffered from severe biventricular heart failure after eight-hour surgery. She is now recovering well in the hospital’s cardiovascular intensive care unit. A man also received a similar artificial heart from the same hospital last month.
Dr Pahwa said that the variable pumping capacity of the Aeson artificial heart increases its viability and improves its performance to meet the body’s changing blood flow needs. The Aeson artificial heart has been approved in Europe and has already been given to 20 people with promising results.
ALSO READ: The success of heart transplants has no age limit: those 70 and over have a survival rate similar to that of younger patients
First North American patient implanted with a CARMAT artificial heart
In July of this year, Duke University and CARMAT announced that surgeons had performed North America’s first implantation of the bioprosthetic artificial heart.
The patient’s name is Mathew Moore, a 39-year-old man from Shallotte, North Carolina. According to Healio, he was referred to Duke University Hospital due to a sudden diagnosis of heart failure that rapidly progressed to the point where conventional options like transplants were no longer viable.
Doctors removed the left and right ventricles before putting the artificial heart in place. Although it was a little difficult because the patient had had surgery the previous month, doctors said the operation went very well. Mr. Moore recovered well after the procedure. The team noted that the artificial heart can adjust so that it doesn’t spend a lot of time adjusting it.
RELATED ARTICLE: ‘Aeson’ Artificial Heart Transplant: 39-Year-Old Man Becomes First US Patient to Undergo Surgery
Find out more about heart health only on Science Times.